Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)
Annals of Clinical Hypertension · 2019
DOI: 10.29328/journal.ach.1001014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Hypertension, 2019. Verfasst von Lizette Arizmendi-Ocampo und 8 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Several epidemiologic studies indicate that up to 50% of patients with heart failure have a preserved ejection fraction, and this proportion has increased over time. The knowledge of its severity and associated comorbidity is determining factor to develop adequate strategies for its treatment and prevention. This study was focus on the creation of a cohort and follow-up of Mexican population and to analyze its severity as well as its interaction with the comorbidity of other cardiovascular risk factors.
Methods
We included patients from different sites of Mexico City than were sent to the Cardiology hospital of the National Medical Center in Mexico City for the realization of an echocardiogram as part of their assessment by the presence of dyspnea, edema, or suspicion of hypertensive heart disease. Complete medical history, physical examination and laboratory studies including Brain Natriuretic Peptide (BNP) serum levels were performed. Diagnosis of diastolic dysfunction was based on symptoms and echocardiographic data including time of deceleration, size of left atrium, e´ septal and e´ lateral, as well as E wave, A wave and its ratio E/A. All patients had left ventricle ejection fraction > 45%.
Results
We included 168 patients with HFpEF. The most common risk factor was hypertension (89.2%), followed by overweight and obesity (> 78.5%), dyslipidemia (82.1%) and diabetes (42.8%). Women were dominant, 108 (64.3%); the mean age was 63 years old. When we classify by severity of diastolic dysfunction, we found that 41.1% were grade I, 57.1% were grade II and only 1.8% were grade III. The risk factors most strongly associated with the severity of diastolic dysfunction were hypertension, obesity and dyslipidemia. We found BNP levels highly variables, but the levels were higher detected as the ejection fraction was approaching to 45%. At one year of follow up mortality was not reported.
Conclusion
HFpEF is a frequent entity in patients with cardiovascular risk factors in Mexico. The most common risk factor was hypertension. The combination of hypertension, overweight and dyslipidemia predicted the severity of diastolic dysfunction. We recommend that all Mexican patient with hypertension and overweight or obesity should be submitted as a part of its medical evaluation to an echocardiogram study in order to detect diastolic dysfunction even though the signs or symptoms are or not evident.
Zitieren
APA
Arizmendi-Ocampo, L., Peralta, M. R., Morales, D. S., Espinosa, A. C., Rodríguez, A. C., Arias, E. R., Kinkel, C. R., Martínez, G. C., & Magaña-Serrano, J. A. (2019). Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS). Annals of Clinical Hypertension. https://doi.org/10.29328/journal.ach.1001014
Vancouver
Arizmendi-Ocampo L, Peralta MR, Morales DS, Espinosa AC, Rodríguez AC, Arias ER, et al. Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS). Annals of Clinical Hypertension. 2019. doi:10.29328/journal.ach.1001014
BibTeX
@article{ArizmendiOcampo2019,
author = {Arizmendi-Ocampo, Lizette and Peralta, Martin Rosas and Morales, Daniela Salinas and Espinosa, Alejandro Chanona and Rodríguez, Alicia Contreras and Arias, Erick Ramírez and Kinkel, Carlos Riera and Martínez, Guadalupe Castro and Magaña-Serrano, José Antonio},
title = {Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)},
journal = {Annals of Clinical Hypertension},
year = {2019},
doi = {10.29328/journal.ach.1001014}
}
EUVIMED